It seems ATI is touchy subject for you Mangoman605, already having convinced yourself only a couple of months after further data in a 5 year trial collaboration, that the J&J trial collaboration with Johnson and Johnson in autologous tenocyte stem cells is done. Done and dusted; "vanished into thin air" even.
I post actual factual developments in the stem cell arena, amongst other information, with relevance to OCC's treatments and declared pathway ambitions and am caller a ramper. You claim J&J's ATI collaboration "vanished into thin air" with absolutely no reason or information to suggest so and apparently feel morally superior?
Yet J&J continues to see success and push forward with.....yep, you guessed it folks....its recently FDA approved autologous stem cell therapy for myeloma:
https://www.jnj.com/u-s-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-a-bcma-directed-car-t-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myelomaHave you borrow someone's magic 8-ball that you can tell us its trial collaboration have vanished into thin air, with the success of its business with another autologous stem cell success going on the background?
What's that? J&J entered into a license agreement with Legend BioTech all the way back in 2017? You mean these things take that long? You mean these things don't unfold in months immediately following trials. What's that? OCC only began its trial collaboration with J&J in 2017?
What's that? J&J's new treatment racked up $55 million in sales in one quarter? A treatment for an affliction that only effects 8 in 100,000 people, unlike tendinosis which literally effects practically every living person on the planet at one point (i.e. 100,000 in 100,000 people):
https://www.fiercepharma.com/marketing/jj-legends-carvykti-nets-55m-sales-all-eyes-car-ts-earlier-myeloma-readoutKeep the negativity coming Mangoman. I mean what was J&J even doing collaborating on this in the first place? They cant really have any other interest in autologous stem cell therapies, which have seen plenty of applications and clearances at the FDA recently.....bah. J&J can't be interested in OCC's silly ATI. They haven't immediately come out and said they are after the data. That's what normally happens isn't it? Seriously? Have you guys ever followed biotech partnerships at all?
Its not even two months after data released on a 5 year trial collaboration:
https://orthocell.com/blog/2022/09/29/ortho-ati-shoulder-tendon-study-update/Did you expect a $200 mill up front, $500 mill milestone payments deal with a few weeks or something?
Congratulations to other OCC shareholders who have conviction in OCC's biotechnologies, being why many of you will be invested in the company in the first place and understand trials, licensing, IP applications, partnerships, etc, do not simply occur overnight.
A nice $0.50 close today. Just reward for your patience and convictions that have been tested by the company's share price, which still defies its forward revenue potential.
(20min delay)